Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAGXK1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:24:45 ON 12 MAY 2008

=> file reg
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                             ENTRY   SESSION
FULL ESTIMATED COST   0.21   0.21

FILE 'REGISTRY' ENTERED AT 18:24:52 ON 12 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAY 2008 HIGHEST RN 1020256-26-1
DICTIONARY FILE UPDATES: 11 MAY 2008 HIGHEST RN 1020256-26-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\mpepitone\My
Documents\STN\10936106\11623996\10561199.str



chain nodes :
10 11 18 19 20 21 22 23 24 25 26 27
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17
chain bonds :
1-10 3-22 7-20 8-21 10-11 11-12 13-18 17-19 22-23 22-27 23-24 24-25
25-26

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-13 12-17 13-14 14-15 15-16
16-17
exact/norm bonds :
1-2 1-6 1-10 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 22-23 22-27 23-24
25-26
exact bonds :
3-22 7-20 8-21 11-12 13-18 17-19 24-25
normalized bonds :
12-13 12-17 13-14 14-15 15-16 16-17

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 exact full
FULL SEARCH INITIATED 18:25:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 22 TO ITERATE

100.0% PROCESSED 22 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L2 2 SEA EXA FUL L1

=> file capl
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST 60.31 60.52

FILE 'CAPLUS' ENTERED AT 18:25:20 ON 12 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 12 May 2008 VOL 148 ISS 20
FILE LAST UPDATED: 11 May 2008 (20080511/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l2
L3 9 L2

=> d l3 1-9 ibib abs hitstr

L3 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:410774 CAPLUS
DOCUMENT NUMBER: 146:421985
TITLE: Preparation of isotopically substituted (deuterated) (fused) imidazopyridines for the treatment of gastrointestinal disorders
INVENTOR(S): Kohl, Bernhard; Zimmermann, Peter Jan; Zech, Karl; Buhr, Wilm; Palmer, Andreas; Brehm, Christof; Chiesa, Maria Vittoria; Kromer, Wolfgang; Postius, Stefan; Simon, Wolfgang-Alexander; Holst, Hans Christof
PATENT ASSIGNEE(S): Altana Pharma AG, Germany
SOURCE: PCT Int. Appl., 62pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007039464	A1	20070412	WO 2006-EP66544	20060920

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: EP 2005-108764 A 20050922
EP 2006-101701 A 20060215

OTHER SOURCE(S): MARPAT 146:421985

GI



I



AB Title compds. [I; R1 = H, alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkenyl, alkynyl, fluoroalkyl, hydroxyalkyl; R2 = H, alkyl, cycloalkyl, cycloalkylalkyl, alkoxycarbonyl, hydroxyalkyl, halo, alkenyl, alkynyl, fluoroalkyl, cyanomethyl; R3 = H, halo, alkyl, fluoroalkyl, CO2H, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, fluoroalkoxyalkyl, etc.; R4, R5 = H, R6 = (substituted) Ph; or R4R5 = CHR7CHR8; R7, R8 = H, OH, alkoxy, cycloalkoxy, cycloalkylalkoxy, alkoxyalkoxy, fluoroalkoxy, hydroxyalkoxy, etc.; or R4 = H, R5R6 = Q1; Z = CHR11, CHR11CHR12; R9 = H, alkyl, hydroxyalkyl, alkoxy, alkenyloxy, aryloxy, etc.; R10 = H, alkyl, alkoxy,, alkoxycarbonyl, halo, CF3, OH; R11, R12 = H, alkyl, alkenyl, OH, alkoxy, alkylcarbonylamino, etc.; X = O, NH; ≥1 of the H atoms of R1-R6 or of the core structure is replaced with D], were prepared Thus, Me 8-[(2,6-dimethylphenyl)dideuteromethylamino]-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate (preparation given) was heated 1 h with ethanolamine to give 73% 8-[(2,6-dimethylphenyl)dideuteromethylamino]-N-(2-hydroxyethyl)-2,3-dimethylimidazo-6-carboxamide. The latter inhibited H+/K+-ATPase with -lg IC50 = 6.0.

IT 934248-01-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of isotopically substituted (deuterated) (fused) imidazopyridines for the treatment of gastrointestinal disorders)

RN 934248-01-8 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(2,6-dimethylphenyl)methyl-d2]amino]-N-(2-hydroxyethyl)-2,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1173242 CAPLUS
DOCUMENT NUMBER: 145:489255
TITLE: Preparation of mutual prodrug compounds for use as antiinflammatory agents with gastrointestinal protective activity
INVENTOR(S): Brehm, Christof; Klein, Thomas; Buhr, Wilm; Chiesa, Maria Vittoria; Palmer, Andreas; Zimmermann, Peter Jan; Simon, Wolfgang-Alexander; Kromer, Wolfgang; Postius, Stefan; Grundler, Gerhard
PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 70pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006117315	A1	20061109	WO 2006-EP61850	20060426
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006243254	A1	20061109	AU 2006-243254	20060426
CA 2605895	A1	20061109	CA 2006-2605895	20060426
EP 1879891	A1	20080123	EP 2006-754865	20060426
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

PRIORITY APPLN. INFO.: EP 2005-103581 A 20050429
WO 2006-EP61850 W 20060426

OTHER SOURCE(S): MARPAT 145:489255

GI



I

AB The invention concerns A-Y-X-z-C(O)O-B (A is derived from ACO2H having antipyretic, analgesic, antiphlogistic and/or antiinflammatory properties; B is derived from HOB that are potassium competitive acid blockers; X = bond or linker (e.g. (un)substituted -(CH2)nOm(CH2)pOq(CH2)r (n = 1-7; m = 0, 1; p = 0-7; q = 0, 1; r = 0-7)); Y = -C(O)O- with A attached to the carbonyl carbon; z = bond, -O-, -CHR1- or -NR1- (R1 = H or C1-4 alkyl); or X, Y and z together form a bond; addnl. details including provisos are given in the claims; e.g. (S)-2-(6-methoxynaphthalen-2-yl)propionic acid 3-[[[(7R,8R,9R)-2,3-dimethyl-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-8-yl]oxy]carbonyl]propyl ester (shown as I)) and their salts. The compds. are prodrugs and exhibit in the human and/or animal body antipyretic, analgesic, antiphlogistic and/or antiinflammatory activity as well as gastric acid secretion inhibiting and therefore gastro and intestinal protective activity. Although the methods of preparation are not claimed, prepns. and/or characterization data for 23 examples of I and similar compds. are included. For example, I was prepared from (S)-2-(6-methoxynaphthalen-2-yl)propionic acid and 4-hydroxybutyric acid (7R,8R,9R)-2,3-dimethyl-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-8-yl ester in THF using DMAP and toluenesulfonyl chloride. Data are provided for the inhibition of gastric acid secretion by 2 examples of I or similar compds. and for inhibition of COX-1/2 by 11 examples of I or similar compds.

IT 248919-64-4, 2,3-Dimethyl-8-[(2,6-dimethylbenzyl)amino]-6-[N-(2-hydroxyethyl)aminocarbonyl]imidazo[1,2-a]pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of mutual prodrug compds. for use as antiinflammatory agents with gastrointestinal protective activity)

RN 248919-64-4 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(2,6-dimethylphenyl)methyl]amino]-N-(2-hydroxyethyl)-2,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:570894 CAPLUS
DOCUMENT NUMBER: 143:83527
TITLE: Crystalline forms of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethylimidazo[1,2-a]pyridine-6-carboxamide mesylate salt
INVENTOR(S): Lilljequist, Lars; Lindkvist, Maria; Nordberg, Peter; Pettersson, Ursula; Sebhatu, Tesfai
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058895	A1	20050630	WO 2004-SE1909	20041216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004299435	A1	20050630	AU 2004-299435	20041216
CA 2549144	A1	20050630	CA 2004-2549144	20041216
EP 1697360	A1	20060906	EP 2004-809082	20041216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1894246	A	20070110	CN 2004-80037988	20041216
BR 2004017640	A	20070327	BR 2004-17640	20041216
JP 2007514744	T	20070607	JP 2006-545292	20041216
IN 2006DN03006	A	20070803	IN 2006-DN3006	20060525
MX 2006PA06708	A	20060818	MX 2006-PA6708	20060613

US 20070112021	A1	20070517	US 2006-582838		20060614
NO 2006003309	A	20060914	NO 2006-3309		20060717
PRIORITY APPLN. INFO.:			SE 2003-3451	A	20031218
			WO 2004-SE1909	W	20041216

AB The present invention relates to novel crystalline forms of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethylimidazo[1,2-a]pyridine-6-carboxamide mesylate salt (I) and to mixture thereof. Further, the present invention also relates to processes for obtaining them, the use of the compds. for the treatment of gastrointestinal disorders, and pharmaceutical compns. containing them. 2,3-Dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethylimidazo[1,2-a]pyridine-6-carboxamide was treated with methanesulfonic acid in EtOH to give crystals of I Form A. The compound was characterized by x-ray crystallog.

IT 248919-64-4
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(crystalline forms of (dimethylbenzylamino)hydroxyethylimidazopyridinecarboxamide)

RN 248919-64-4 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(2,6-dimethylphenyl)methyl]amino]-N-(2-hydroxyethyl)-2,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2005:409313 CAPLUS
DOCUMENT NUMBER:	142:457095
TITLE:	Imidazo [1,2-a] pyridine derivatives for the treatment of silent gastro-esophageal reflux
INVENTOR(S):	Fernstroem, Paula; Hasselgren, Goeran
PATENT ASSIGNEE(S):	Astrazeneca AB, Swed.
SOURCE:	PCT Int. Appl., 40 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041961	A1	20050512	WO 2004-SE1589	20041103
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004285394	A1	20050512	AU 2004-285394		20041103
CA 2544325	A1	20050512	CA 2004-2544325		20041103
EP 1682133	A1	20060726	EP 2004-800252		20041103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS					
CN 1874772	A	20061206	CN 2004-80032415		20041103
IN 2006DN01943	A	20070803	IN 2006-DN1943		20060410
NO 2006002570	A	20060803	NO 2006-2570		20060602
PRIORITY APPLN. INFO.:			US 2003-517125P	P	20031103
			WO 2004-SE1589	W	20041103

OTHER SOURCE(S): MARPAT 142:457095

GI



I

AB The present invention relates to a new method of treatment of sleep disturbance due to silent gastro-esophageal reflux. The invention further relates to the use of potassium-competitive acid blockers (P-CAB's) which inhibit the enzyme responsible for gastric acid secretion (H+/K+-ATPase). In particular, the present invention relates to the use of certain imidazo (1,2-a)pyridines derivs. (I wherein R1 = H, Me or Et: R2 = Me or Et; R3 and R4 = H, C1-6 alkyl, hydroxylated C1-6 alkyl or halogen; R5 = H or halogen; R6 and R7 = H, C1-6 alkyl, hydroxylated C1-6 alkyl or C1-6 alkoxy-substituted C1-6 alkyl and X = NH or O) in said treatment.

IT 248919-64-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(imidazo[a]pyridine derivs. for treatment of silent gastro-esophageal reflux and sleep disturbances in relation to potassium-competitive acid secretion blockade)

RN 248919-64-4 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(2,6-dimethylphenyl)methyl]amino]-N-(2-hydroxyethyl)-2,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1059201 CAPLUS
DOCUMENT NUMBER: 142:32977
TITLE: Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
INVENTOR(S): Zimmermann, Peter Jan; Chiesa, M. Vittoria; Palmer, Andreas; Brehm, Christof; Klein, Thomas; Senn-Bilfinger, Joerg; Simon, Wolfgang-Alexander; Kromer, Wolfgang; Grundler, Gerhard; Hanauer, Guido; Buhr, Wilm; Postius, Stefan
PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004105795	A1	20041209	WO 2004-EP50936	20040526
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004243444	A1	20041209	AU 2004-243444	20040526
CA 2526566	A1	20041209	CA 2004-2526566	20040526
EP 1644043	A1	20060412	EP 2004-741658	20040526
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006528231	T	20061214	JP 2006-530222	20040526
MX 2005PA12463	A	20060130	MX 2005-PA12463	20051118
US 20060241134	A1	20061026	US 2005-557414	20051118

NO 2005005968 A 20051215 NO 2005-5968 20051215
PRIORITY APPLN. INFO.: EP 2003-11875 A 20030527
EP 2004-102304 A 20040525
WO 2004-EP50936 W 20040526

AB The invention relates to the combination of certain active compds. from the acid pump antagonist class and compds. which modify gastrointestinal motility. The acid pump antagonist class is selected from a tricyclic imidazopyridine and the gastrointestinal motility modifier is selected from a 5-HT-(partial)-agonist/antagonist.

IT 248919-64-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical combinations of proton pump inhibitor and modifier of gastrointestinal motility)

RN 248919-64-4 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(2,6-dimethylphenyl)methyl]amino]-N-(2-hydroxyethyl)-2,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:913040 CAPLUS
DOCUMENT NUMBER: 139:375018
TITLE: Combinations containing proton pump inhibitors for the treatment of airway disorders
INVENTOR(S): Hanauer, Guido; Kromer, Wolfgang; Postius, Stefan; Simon, Wolfgang-Alexander
PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003094967	A2	20031120	WO 2003-EP4653	20030503
WO 2003094967	A3	20040401		

W: AE, AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE,

DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR

AU 2003227710	A1	20031111	AU 2003-227710	20030503
CA 2484272	A1	20031120	CA 2003-2484272	20030503
EP 1506016	A2	20050216	EP 2003-725140	20030503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009808	A	20050301	BR 2003-9808	20030503
CN 1652822	A	20050810	CN 2003-810400	20030503
JP 2005528418	T	20050922	JP 2004-503050	20030503
IN 2004MN00536	A	20050513	IN 2004-MN536	20040928
ZA 2004007896	A	20060628	ZA 2004-7896	20040930
MX 2004PA11018	A	20050125	MX 2004-PA11018	20041105
US 20050222193	A1	20051006	US 2004-513598	20041105
NO 2004005343	A	20041206	NO 2004-5343	20041206
PRIORITY APPLN. INFO.:			EP 2002-10305 A	20020507
			WO 2003-EP4653 W	20030503

AB A method for treating airway disorders comprises a reversible proton pump inhibitor and an airway therapeutic to be taken simultaneously (as a fixed oral combination) or in succession (one directly after the other or else within a relatively large time span). The reversible proton pump inhibitor is, e.g., Soraprazan or its salt, and the airway therapeutic is, e.g., Ciclesonide.

IT 248919-64-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral combination of reversible proton pump inhibitors and airway therapeutics for treatment of airway disorders)

RN 248919-64-4 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(2,6-dimethylphenyl)methyl]amino]-N-(2-hydroxyethyl)-2,3-dimethyl- (CA INDEX NAME)



L3 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2002:637503 CAPLUS
DOCUMENT NUMBER:	137:190728
TITLE:	Novel modified release formulation containing carboxamide derivatives for inhibition of secretion of gastric acid
INVENTOR(S):	Juppo, Anne
PATENT ASSIGNEE(S):	Astrazeneca Ab, Swed.
SOURCE:	PCT Int. Appl., 35 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002064118	A1	20020822	WO 2002-SE227		20020208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2434542	A1	20020822	CA 2002-2434542		20020208
AU 2002230344	A1	20020828	AU 2002-230344		20020208
EP 1361868	A1	20031119	EP 2002-711597		20020208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
CN 1491105	A	20040421	CN 2002-804906		20020208
CN 1491104	A	20040421	CN 2002-804914		20020208
JP 2004518708	T	20040624	JP 2002-563914		20020208
NZ 526993	A	20050128	NZ 2002-526993		20020208
AT 324871	T	20060615	AT 2002-710645		20020208
PT 1368006	T	20060831	PT 2002-710645		20020208
ES 2261643	T3	20061116	ES 2002-710645		20020208
ZA 2003005944	A	20050311	ZA 2003-5944		20030731
US 20040067252	A1	20040408	US 2003-467723		20030811
PRIORITY APPLN. INFO.:			SE 2001-477	A	20010213
			SE 2001-478	A	20010213
			WO 2002-SE227	W	20020208

OTHER SOURCE(S): MARPAT 137:190728
GI



I

AB A multiparticulate (particle size < 300 μm), modified-release solid dispersion formulation comprises (i) a drug substance having a pH-dependent solubility, i.e., compound I (R1 = H, Me, Et; R2 = Me, Et; R3, R4 = H, C1-6 alkyl, hydroxylated C1-6 alkyl, halogen; R5 = H, halogen; R6, R7 = H, C1-6 alkyl, hydroxylated C1-6 alkyl, C1-6 alkoxy-substituted C1-6 alkyl; X = NH, O) or a pharmaceutically acceptable salt thereof; (ii) a

hydrophobic matrix former which is a water-insol., non-swelling amphiphilic lipid; and (iii) a hydrophilic matrix former which is a meltable, water-soluble excipient. The weight ratio of hydrophobic matrix former/hydrophilic matrix former is ≥1 and the particle size is less than 300 μm. Also a unit dosage form of the compound I, as well as a process for its preparation, and the use of the formulation and unit dosage form for inhibiting the secretion of gastric acid are described. For example, multiparticulate, modified-release formulation was prepared by dissolving 1 g of 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)imidazo[1,2-a]pyridine-6-carboxamide mesylate in a melt of 4 g myristic acid at 90° and adding 2 g of polyethylene glycol 4000 (PEG 4000) into the melt. The melted mixture was atomized at 90° and the particles were collected into a vessel which was kept on ice. The resulted particles were spherical and < 300 μm in size. The amount of 3 g of particles were blended with 5.85 g microcryst. cellulose and 0.016 g sodium stearyl fumarate and compressed into 450 mg tablets. The dissoln. of tablets was 52-56% in 3 h.

IT 248919-64-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release formulation containing imidazopyridine carboxamide derivs. for inhibition of gastric acid secretion)

RN 248919-64-4 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(2,6-dimethylphenyl)methyl]amino]-N-(2-hydroxyethyl)-2,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:185119 CAPLUS
DOCUMENT NUMBER: 136:249369
TITLE: Process for preparing a substituted imidazopyridine compound
INVENTOR(S): Elman, Bjoern; Erback, Silke; Thiemermann, Eric
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002020523	A1	20020314	WO 2001-SE1897	20010905
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2419764	A1	20020314	CA 2001-2419764	20010905
AU 2001084594	A	20020322	AU 2001-84594	20010905
EP 1317455	A1	20030611	EP 2001-963665	20010905
EP 1317455	B1	20040804		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013602	A	20030715	BR 2001-13602	20010905
HU 2003002277	A2	20031028	HU 2003-2277	20010905
HU 2003002277	A3	20031229		
HU 225459	B1	20061228		
JP 2004508371	T	20040318	JP 2002-525144	20010905
AT 272637	T	20040815	AT 2001-963665	20010905
NZ 524302	A	20040827	NZ 2001-524302	20010905
PT 1317455	T	20041130	PT 2001-963665	20010905
EE 200300090	A	20041215	EE 2003-90	20010905
ES 2223906	T3	20050301	ES 2001-963665	20010905
CZ 294957	B6	20050413	CZ 2003-643	20010905
AU 2001284594	B2	20051215	AU 2001-284594	20010905
RU 2275372	C2	20060427	RU 2003-104987	20010905
ZA 2003001171	A	20040318	ZA 2003-1171	20030212
IN 2003MN00220	A	20060505	IN 2003-MN220	20030214
MX 2003PA01941	A	20030624	MX 2003-PA1941	20030305
NO 2003001046	A	20030505	NO 2003-1046	20030306
NO 324252	B1	20070917		
KR 770478	B1	20071026	KR 2003-703311	20030306
US 20040039013	A1	20040226	US 2003-363806	20030627
US 6900324	B2	20050531		
HK 1054388	A1	20050408	HK 2003-106657	20030916
US 20060063797	A1	20060323	US 2005-107352	20050414

PRIORITY APPLN. INFO.:

SE 2000-3186	A	20000907
WO 2001-SE1897	W	20010905
US 2003-363806	A1	20030627

OTHER SOURCE(S): MARPAT 136:249369

GI



I



II

AB Present invention provides a new process for large-scale preparation of substituted imidazopyridine compound of formula (I), wherein R1 = C1-6

alkoxy or NH2 group, comprising the step of reacting a compound of formula (II) with a 3-halo-2-butanone compound in cyclohexanone. Thus, 5.1 g 5,6-diaminonicotinic acid Me ester, 50 mL cyclohexanone, and 3.9 mL bromobutanone were agitated at 100° for 2.5 h to give Me 8-amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate.

IT 248919-64-4P
RL: IMF (Industrial manufacture); PREP (Preparation)
(process for preparing a substituted imidazopyridine compound)

RN 248919-64-4 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(2,6-dimethylphenyl)methyl]amino]-N-(2-hydroxyethyl)-2,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:708770 CAPLUS

DOCUMENT NUMBER: 131:322617

TITLE: Preparation of imidazopyridines which inhibit gastric acid secretion

INVENTOR(S): Amin, Kosrat; Dahlstrom, Michael; Nordberg, Peter; Starke, Ingemar

PATENT ASSIGNEE(S): Astra AB, Swed.

SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9955706	A1	19991104	WO 1999-SE663	19990423
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TW 490466	B	20020611	TW 1999-88106129	19990416
TW 250159	B	20060301	TW 1999-88106128	19990416

CA 2329922	A1	19991104	CA 1999-2329922		19990423
CA 2329922	C	20060411			
AU 9943007	A	19991116	AU 1999-43007		19990423
AU 769190	B2	20040122			
BR 9909996	A	20001226	BR 1999-9996		19990423
EP 1073657	A1	20010207	EP 1999-947038		19990423
EP 1073657	B1	20051207			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY					
TR 200003149	T2	20010321	TR 2000-3149		19990423
TR 200003176	T2	20010321	TR 2000-3176		19990423
HU 2001002425	A2	20011128	HU 2001-2425		19990423
HU 2001002425	A3	20021228			
EE 200000664	A	20020415	EE 2000-664		19990423
EE 4916	B1	20071015			
JP 2002513025	T	20020508	JP 2000-545865		19990423
JP 3692034	B2	20050907			
TR 200102612	T2	20020621	TR 2001-2612		19990423
TR 200102728	T2	20020621	TR 2001-2728		19990423
CZ 292567	B6	20031015	CZ 2000-3982		19990423
NZ 507639	A	20040130	NZ 1999-507639		19990423
CZ 293977	B6	20040915	CZ 2000-3981		19990423
RU 2238271	C2	20041020	RU 2000-127019		19990423
EP 1491542	A2	20041229	EP 2004-23090		19990423
EP 1491542	A3	20050105			
EP 1491542	B1	20070905			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY					
EP 1491543	A1	20041229	EP 2004-23091		19990423
EP 1491543	B1	20070905			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY					
AT 312101	T	20051215	AT 1999-947038		19990423
ES 2249913	T3	20060401	ES 1999-947037		19990423
ES 2252975	T3	20060516	ES 1999-947038		19990423
SK 285768	B6	20070706	SK 2000-1492		19990423
PL 195000	B1	20070731	PL 1999-343801		19990423
AT 372339	T	20070915	AT 2004-23090		19990423
AT 372340	T	20070915	AT 2004-23091		19990423
US 6313137	B1	20011106	US 1999-319973		19990614
IN 2000MN00497	A	20050318	IN 2000-MN497		20001012
ZA 2000005796	A	20020118	ZA 2000-5796		20001018
ZA 2000005797	A	20020118	ZA 2000-5797		20001018
MX 2000PA10239	A	20010405	MX 2000-PA10239		20001019
NO 2000005450	A	20001222	NO 2000-5450		20001027
NO 317262	B1	20040927			
HK 1071140	A1	20080215	HK 2005-103979		20010612
HK 1033317	A1	20060630	HK 2001-104064		20010613
HK 1036984	A1	20050429	HK 2001-107857		20011108
PRIORITY APPLN. INFO.:			SE 1998-1526	A	19980429
			EP 1999-947037	A3	19990423
			EP 1999-947038	A3	19990423
			WO 1999-SE663	W	19990423
			HK 2001-104026	A3	20010612

OTHER SOURCE(S): MARPAT 131:322617

GI



I

AB The title compds. [I; R1 = H, Me, CH2OH; R2 = Me, Et; R3 = H, alkyl, halo, etc.; R4 = H, alkyl, halo, etc.; R5 = H, halo; R6, R7 = H, alkyl, hydroxylated alkyl, etc.; X = NH, O] which inhibit exogenously or endogenously stimulated gastric acid secretion (no data) and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases, and for treatment or prophylaxis of conditions involving infection by Helicobacter pylori of human gastric mucosa, were prepared Thus, reacting Et 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylate with propylamine in the presence of a cat. amount of NaCN in MeOH afforded 42% I [R1 = R2 = R4 = Me; R3 = Et; R5 = R7 = H; R6 = Pr]. In general, compds. I are effective at 5-1000 mg/day.

IT 248919-64-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridines which inhibit gastric acid secretion)

RN 248919-64-4 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(2,6-dimethylphenyl)methyl]amino]-N-(2-hydroxyethyl)-2,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> FIL STNGUIDE
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      49.53     110.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -7.20      -7.20

FILE 'STNGUIDE' ENTERED AT 18:26:04 ON 12 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May  9, 2008 (20080509/UP).

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.30     110.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -7.20

STN INTERNATIONAL LOGOFF AT 18:29:01 ON 12 MAY 2008
```